Form 4: Aprea Therapeutics Director Rifat Pamukcu Reports Acquisition of Common Stock and Stock Options

Director Rifat Pamukcu reported the acquisition of common stock and stock options in Aprea Therapeutics, Inc. on June 20, 2024.

Summary

• On June 20, 2024, Rifat Pamukcu, a director of Aprea Therapeutics, Inc., acquired 1,045 shares of common stock and 4,185 stock options.
• The common stock was acquired through restricted stock units granted on June 20, 2024, which will vest on June 20, 2025, contingent upon continued service on the board.
• The stock options, with an exercise price of $4.07, also vest on June 20, 2025, subject to continued board service.
• Pamukcu also indirectly owns 14,108 shares of common stock through ZNZ Holdings LLC, where he serves as Manager Partner.
• Following the reported transactions, Pamukcu directly owns 4,401 shares of common stock and 4,185 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating insider transactions. The acquisition of shares and options can be seen as a positive sign, but it's not overwhelmingly bullish.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future prospects.
• The vesting conditions tied to continued service align the director's interests with the long-term success of the company.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of shares and options is contingent on continued service, suggesting an expectation of ongoing involvement.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide investors with insights into the actions of company insiders, such as directors and officers.

Stakeholder Impact

• Shareholders may view the director's acquisition of shares and options as a positive signal, indicating confidence in the company's future.
• The vesting conditions tied to continued service align the director's interests with the long-term success of the company, potentially benefiting all stakeholders.

Key Dates